TRANSCENTA-B (06628) released its interim results, reporting a shareholder loss of 67.347 million yuan, a year-on-year reduction of 38.66%.
Chuangsheng Group Pharmaceutical-B (06628) announced its interim results for the six months ended June 30, 2026, reporting revenue of 23.597 million yuan, an increase of 770.42% year-on-year. The loss attributable to the company's owners narrowed to 67.347 million yuan, a decrease of 38.66% year-on-year. The loss per share is 0.27 yuan.
TRANSCENTA-B (06628) announced its interim results for the six months ending June 30, 2026, reporting revenue of 23.597 million yuan, a year-on-year increase of 770.42%; the loss attributable to the companys shareholders narrowed by 38.66% to 67.347 million yuan; loss per share was 0.27 yuan. Loss per share was 0.16 yuan.
The announcement stated that the increase in revenue was primarily due to growth in external licensing income and CDMO services.
Related Articles
BBMG (02009) subsidiary obtains real estate project.
FDB HOLDINGS (01826) released its interim results, with a shareholder loss of HK$10.348 million, a year-on-year increase of 100.4%.
LANDSEA LIFE (01965) released its interim results, with profit attributable to shareholders reaching HK$ 5.618 million, an increase of 230.28% year-on-year.
BBMG (02009) subsidiary obtains real estate project.
FDB HOLDINGS (01826) released its interim results, with a shareholder loss of HK$10.348 million, a year-on-year increase of 100.4%.
LANDSEA LIFE (01965) released its interim results, with profit attributable to shareholders reaching HK$ 5.618 million, an increase of 230.28% year-on-year.
RECOMMEND
